Cell transplantation for Huntingtons disease: Practical and clinical considerations

Future Neurology

Volumn 6, Issue 1, 2011, Pages 45-62

  Rosser, Anne E ^a,b   Kelly, Claire M ^a   Dunnett, Stephen B ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

clinical trial; Huntingtons disease; neural transplantation; stem cell; therapy

Indexed keywords

BRAIN NERVE CELL; CELL FUNCTION; CELL REGENERATION; CELL TRANSPLANTATION; CLINICAL TRIAL; CORPUS STRIATUM; DONOR SELECTION; EMBRYONIC STEM CELL; ENGRAFTMENT; FETAL STEM CELL; FEVER; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUNTINGTON CHOREA; KIDNEY DYSFUNCTION; LYMPHOCYTOSIS; MEDICAL ETHICS; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; PATIENT SAFETY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; SUBDURAL HEMATOMA; TASK PERFORMANCE; TREATMENT OUTCOME;

EID: 78650648456     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/fnl.10.78     Document Type: Review

References (157)

1. Spinney L: Uncovering the true prevalence of Huntingtons disease. Lancet Neurol. 9(8), 760-761 (2010).
2. Huntingtons Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons disease chromosomes. Cell 72, 971-983 (1993).
3. Walker FO: Huntingtons disease. Lancet 369(9557), 218-228 (2007).
4. Gil JM, Rego AC: Mechanisms of neurodegeneration in Huntingtons disease. Eur. J. Neurosci. 27(11), 2803-2820 (2008).
5. Graveland GA, Williams RS, DiFiglia M: Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntingtons disease. Science 227(4688), 770-773 (1985).
6. Novak MJ, Tabrizi SJ: Huntingtons disease. BMJ 340, C3109 (2010).
7. Rickards H, De Souza J, van Walsem M et al.: Factor analysis of behavioral symptoms in Huntingtons disease. J. Neurol. Neurosurg. Psychiatry DOI:10.1136/jnnp.2009.181149 (2010) (Epub ahead of print).
8. Ferrante RJ: Mouse models of Huntingtons disease and methodological considerations for therapeutic trials. Biochim. Biophys. Acta 1792(6), 506-520 (2009).
9. Björklund A, Schmidt RH, Stenevi U: Functional reinnervation of the neostriatum in the adult rat by use of intraparenchymal grafting of dissociated cell suspensions from the substantia nigra. Cell Tiss. Res. 212, 39-45 (1980).
10. Schmidt RH, Björklund A, Stenevi U: Intracerebral grafting of dissociated CNS tissue suspensions: a new approach for neuronal transplantation to deep brain sites. Brain Res. 218, 347-356 (1981).
11. Isacson O, Brundin P, Kelly PAT, Gage FH, Björklund A: Functional neuronal replacement by grafted striatal neurons in the ibotenic acid lesioned rat striatum. Nature 311, 458-460 (1984).
12. Fricker RA, Barker RA, Fawcett JW, Dunnett SB: A comparative study of preparation techniques for improving the viability of striatal grafts using vital stains, in vitro cultures and in vivo grafts. Cell Transplant. 5(6), 599-611 (1996).
13. Sanberg PR, Coyle JT: Scientific approaches to Huntingtons disease. CRC Crit. Rev. Clin. Neurobiol. 1, 1-44 (1984).
14. Brouillet E, Jacquard C, Bizat N, Blum D: 3-nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntingtons disease. J. Neurochem. 95(6), 1521-1540 (2005).
15. Alberch J, Pérez-Navarro E, Canals JM: Animal models of Huntingtons disease. In: Encyclopedia of Neuroscience. Squire LR (Ed.). Elsevier, MO, USA, 429-436 (2009).
16. Davies SW, Turmaine M, Cozens BA et al.: Formation of neuronal intranuclear inclusions (NII) underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90(3), 537-548 (1997).
17. DiFiglia M, Sapp E, Chase KO et al.: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993 (1997).
18. Morton AJ, Lagan M, Skepper JN, Dunnett SB: Progressive formation of inclusions in the brains of mice transgenic for the human Huntingtons disease mutation parallels neurological decline. J. Neurocytol. 29(9), 679-702 (2000).
19. Dunnett SB, Carter RJ, Watts C et al.: Striatal transplantation in a transgenic mouse model of Huntingtons disease. Exp. Neurol. 154, 31-40 (1998).
20. Dunnett SB, Nathwani F, Björklund A: The integration and function of striatal grafts. Prog. Brain Res. 127, 345-380 (2000).
21. Isacson O, Brundin P, Gage FH, Björklund A: Neural grafting in a rat model of Huntingtons disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting. Neuroscience 16, 799-817 (1985).
22. Wictorin K, Ouimet CC, Björklund A: Intrinsic organization and connectivity of intrastriatal striatal transplants in rats as revealed by DARPP-32 immunohistochemistry: specificity of connections with the lesioned host brain. Eur. J. Neurosci. 1, 690-701 (1989).
23. Clarke DJ, Wictorin K, Dunnett SB, Bolam JP: Internal composition of striatal grafts: light and electron microscopy. In: The Basal Ganglia IV. New Ideas on Structure and Function. Percheron G, McKenzie JS, Féger J (Eds). Plenum Press, NY, USA, 189-196 (1994).
24. Graybiel AM, Liu FC, Dunnett SB: Intrastriatal grafts derived from fetal striatal primordia. 1. Phenotypy and modular organization. J. Neurosci. 9, 3250-3271 (1989).
25. Helm GA, Palmer PE, Bennett JP: Choline acetyltransferase- and substance P-like immunoreactive elements in fetal striatal grafts in the rat: a correlated light and electron microscopic study. Neuroscience 47, 621-639 (1992).
26. Pakzaban P, Deacon TW, Burns LH, Isacson O: Increased proportion of acetylcholinesterase-rich zones and improved morphological integration in host striatum of fetal grafts derived from the lateral but not the medial ganglionic eminence. Exp. Brain Res. 97, 13-22 (1993).
27. Deacon TW, Pakzaban P, Isacson O: The lateral ganglionic eminence is the origin of cells committed to striatal phenotypes: neural transplantation and developmental evidence. Brain Res. 668, 211-219 (1994).
28. Olsson M, Campbell K, Wictorin K, Björklund A: Projection neurons in fetal striatal transplants are predominantly derived from the lateral ganglionic eminence. Neuroscience 69(4), 1169-1182 (1995).
29. Olsson M, Björklund A, Campbell K: Early specification of striatal projection neurons and interneuronal subtypes in the lateral and medial ganglionic eminence. Neuroscience 84, 867-876 (1998).
30. Liu FC, Dunnett SB, Graybiel AM: Intrastriatal grafts derived from embryonic striatal primordia. IV. Migratory capability of host striatal neurons. Neuroscience 55, 363-372 (1993).
31. Wictorin K, Brundin P, Gustavii B, Lindvall O, Björklund A: Reformation of long axon pathways in adult rat central nervous system by human forebrain neuroblasts. Nature 347, 556-558 (1990).
32. Clarke DJ, Dunnett SB, Isacson O, Sirinathsinghji DJS, Björklund A: Striatal grafts in rats with unilateral neostriatal lesions. I. Ultrastructural evidence of afferent synaptic inputs from the host nigrostriatal pathway. Neuroscience 24, 791-801 (1988).
33. Clarke DJ, Dunnett SB: Synaptic relationships between cortical and dopaminergic inputs and intrinsic GABAergic systems within intrastriatal striatal grafts. J. Chem. Neuroanat. 6, 147-158 (1993).
34. Liu FC, Graybiel AM, Dunnett SB, Baughman RW: Intrastriatal grafts derived from fetal striatal primordia. 2. Reconstitution of cholinergic and dopaminergic systems. J. Comp. Neurol. 295, 1-14 (1990).
35. Campbell K, Wictorin K, Björklund A: Differential regulation of neuropeptide mRNA expression in intrastriatal striatal transplants by host dopaminergic afferents. Proc. Natl Acad. Sci. USA 89, 10489-10493 (1992).
36. Campbell K, Kalén P, Wictorin K, Lundberg C, Mandel RJ, Björklund A: Characterization of GABA release from intrastriatal striatal transplants: dependence on host-derived afferents. Neuroscience 53, 403-415 (1993).
37. Wictorin K, Isacson O, Fischer W, Nothias F, Peschanski M, Björklund A: Connectivity of striatal grafts implanted into the ibotenic acid- lesioned striatum. 1. Subcortical afferents. Neuroscience 27, 547-562 (1988).
38. Wictorin K, Clarke DJ, Bolam JP, Björklund A: Host corticostriatal fibres establish synaptic connections with grafted striatal neurons in the ibotenic acid lesioned striatum. Eur. J. Neurosci. 1, 189-195 (1989).
39. Wictorin K: Anatomy and connectivity of intrastriatal striatal transplants. Prog. Neurobiol. 38, 611-639 (1992).
40. Pritzel M, Isacson O, Brundin P, Wiklund L, Björklund A: Afferent and efferent connections of striatal grafts implanted into the ibotenic acid lesioned neostriatum in adult rats. Exp. Brain Res. 65, 112-126 (1986).
41. Wictorin K, Clarke DJ, Bolam JP, Björklund A: Fetal striatal neurons grafted into the ibotenate lesioned adult striatum: efferent projections and synaptic contacts in the host globus pallidus. Neuroscience 37, 301-315 (1990).
42. Kelly CM, Precious SV, Penketh R, Amso NN, Dunnett SB, Rosser AE: Striatal graft projections are influenced by donor cell type and not the immunogenic background. Brain 130(5), 1317-1329 (2007).
43. Magavi SS, Lois C: Transplanted neurons form both normal and ectopic projections in the adult brain. Dev. Neurobiol. 68(14), 1527-1537 (2008).
44. Rutherford A, Garcia-Muoz M, Dunnett SB, Arbuthnott GW: Electrophysiological demonstration of host cortical inputs to striatal grafts. Neurosci. Lett. 83, 275-281 (1987).
45. Xu ZC, Wilson CJ, Emson PC: Synaptic potentials evoked in spiny neurons in rat neostriatal grafts by cortical and thalamic stimulation. J. Neurophysiol. 65, 477-493 (1991).
46. Mazzocchi-Jones D, Döbrössy MD, Dunnett SB: Synaptic plasticity in striatal grafts. Eur. J. Neurosci. 30(11), 2134-2142 (2009).
47. Siviy SM, Walsh JP, Radisavljevic Z, Cohen RW, Buchwald NA, Levine MS: Evidence for enhanced synaptic excitation in transplanted neostriatal neurons. Exp. Neurol. 123, 222-234 (1993).
48. Sirinathsinghji DJS, Dunnett SB, Isacson O, Clarke DJ, Kendrick K, Björklund A: Striatal grafts in rats with unilateral neostriatal lesions. II. In vivo monitoring of GABA release in globus pallidus and substantia nigra. Neuroscience 24, 803-811 (1988).
49. Deckel AW, Robinson RG, Coyle JT, Sanberg PR: Reversal of long-term locomotor abnormalities in the kainic acid model of Huntingtons disease by day 18 fetal striatal implants. Eur. J. Pharmacol. 92, 287-288 (1983).
50. Deckel AW, Moran TH, Coyle JT, Sanberg PR, Robinson RG: Anatomical predictors of behavioral recovery following fetal striatal transplants. Brain Res. 365, 249-258 (1986).
51. Isacson O, Dunnett SB, Björklund A: Graft-induced behavioral recovery in an animal model of Huntington disease. Proc. Natl Acad. Sci. USA 83, 2728-2732 (1986).
52. Dunnett SB, White A: Striatal grafts alleviate bilateral striatal lesion deficits in operant delayed alternation in the rat. Exp. Neurol. 199(2), 479-489 (2006).
53. Giordano M, Salado-Castillo R, Snchez-Alavez M, Prado-Alcal RA: Striatal transplants prevent AF64A-induced retention deficits. Life Sci. 63(22), 1953-1961 (1998).
54. Brasted PJ, Watts C, Robbins TW, Dunnett SB: Associative plasticity in striatal transplants. Proc. Natl Acad. Sci. USA 96, 10524-10529 (1999).
55. Mayer E, Brown VJ, Dunnett SB, Robbins TW: Striatal graft-associated recovery of a lesion-induced performance deficit in the rat requires learning to use the transplant. Eur. J. Neurosci. 4, 119-126 (1992).
56. Brasted PJ, Robbins TW, Dunnett SB: Behavioral recovery after transplantation into a rat model of Huntingtons disease requires both anatomical connectivity and extensive postoperative training. Behav. Neurosci. 114(2), 431-436 (2000).
57. Döbrössy MD, Dunnett SB: The influence of environment and experience on neural grafts. Nat. Rev. Neurosci. 2(12), 871-879 (2001).
58. Barker RA, Kendall AL, Widner H, Dunnett SB; European Biomed Xenotransplantation Program: Neural tissue xenotransplantation: what is needed prior to clinical trials? Cell Transplant. 9(2), 235-246 (2000).
59. Brundin P, Strecker RE, Widner H et al.: Human fetal dopamine neurons grafted in a rat model of Parkinsons disease: immunological aspects, spontaneous and drug- induced behavior, and dopamine release. Exp. Brain Res. 70, 192-208 (1988).
60. Pakzaban P, Isacson O: Neural xenotransplantation: reconstruction of neuronal circuitry across species barriers. Neuroscience 62, 989-1001 (1994).
61. Kelly CM, Precious SV, Scherf C et al.: Neonatal desensitization allows long-term survival of neuronal xenotransplants without immunosuppression. Nat. Methods 6(4), 271-273 (2009).
62. Polkinghorne J, Hoffenberg R, Kennedy I, Macintyre S: Review of the Guidance on the Research Use of Fetuses and Fetal Material. Her Majestys Stationary Office, UK (1989).
63. Unger C, Skottman H, Blomberg P, Dilber MS, Hovatta O: Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum. Mol. Genet. 17(R1), R48-R53 (2008).
64. Bachoud-Lévi AC, Rémy P, Nguyen JP et al.: Motor and cognitive improvements in patients with Huntingtons disease after neural transplantation. Lancet 356(9246), 1975-1979 (2000).
65. Bachoud-Lévi AC, Gaura V, Brugières P et al.: Persistent benefit of foetal neural transplants in patients with Huntingtons disease 6 years after surgery. Lancet Neurol. 5(4), 303-309 (2006).
66. Capetian P, Knoth R, Maciaczyk J et al.: Histological findings on fetal striatal grafts in a Huntingtons disease patient early after transplantation. Neuroscience 160(3), 661-675 (2009).
67. Gallina P, Paganini M, Di Rita A et al.: Human fetal striatal transplantation in Huntingtons disease: a refinement of the stereotactic procedure. Stereotact. Funct. Neurosurg. 86(5), 308-313 (2008).
68. Hauser RA, Furtado S, Cimino CR et al.: Bilateral human fetal striatal transplantation in Huntingtons disease. Neurology 58(5), 687-695 (2002).
69. Kopyov OV, Jacques S, Lieberman A, Duma CM, Eagle KS: Safety of intrastriatal neurotransplantation for Huntingtons disease patients. Exp. Neurol. 119(1), 97-108 (1998).
70. Reuter I, Tai YF, Pavese N et al.: Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntingtons disease. J. Neurol. Neurosurg. Psychiat. 79(8), 948-951 (2008).
71. Rosser AE, Barker RA, Guillard J et al.: Unilateral transplantation of human primary fetal tissue in four patients with Huntingtons disease: NEST-UK safety report (ISRCTN no 36485475). J. Neurol. Neurosurg. Psychiat. 73(6), 678-685 (2002).
72. Boer GJ, Widner H: Clinical neurotransplantation: core assessment protocol rather than sham surgery as control. Brain Res. Bull. 58, 547-553 (2002).
73. Quinn NP, Brown R, Craufurd D et al.: Core assessment programme for intracerebral transplantation in Huntingtons disease (CAPIT-HD). Mov. Disord. 11(2), 143-150 (1996).
74. Hurelbrink CB, Armstrong RJE, Barker RA, Dunnett SB, Rosser AE: Hibernated human fetal striatal tissue: successful transplantation in a rat model of Huntingtons disease. Cell Transplant. 9(6), 743-749 (2000).
75. Hurelbrink CB, Tyers P, Armstrong RJE, Dunnett SB, Barker RA, Rosser AE: Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntingtons disease. Cell Transplant. 12(7), 687-695 (2003).
76. Brundin P, Fricker RA, Nakao N: Paucity of P-zones in striatal grafts prohibit commencement of clinical trials in Huntingtons disease. Neuroscience 71(3), 895-897 (1996).
77. Grasbon-Frodl EM, Nakao N, Lindvall O, Brundin P: Phenotypic development of the human embryonic striatal primordium: a study of cultured and grafted neurons from the lateral and medial ganglionic eminence. Neuroscience 73, 171-183 (1996).
78. Gallina P, Paganini M, Lombardini L et al.: Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntingtons disease patients after transplantation. Exp. Neurol. 222(1), 30-41 (2010).
79. Folkerth RD, Durso R: Survival and proliferation of non-neural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. Neurology 46(5), 1219-1225 (1996).
80. Mamelak AN, Eggerding FA, Oh DS et al.: Fatal cyst formation after fetal mesencephalic allograft transplant for Parkinsons disease. J. Neurosurg. 89(4), 592-598 (1998).
81. Keene CD, Chang RC, Leverenz JB et al.: A patient with Huntingtons disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol. 117(3), 329-338 (2009).
82. Freeman TB, Cicchetti F, Bachoud-Lévi AC, Dunnett SB: Technical factors that influence neural transplant safety in Huntingtons disease. Exp. Neurol. DOI:10.1016/j. expneurol.2010.08.031 (2010) (Epub ahead of print).
83. Gaura V, Bachoud-Lévi AC, Ribeiro MJ et al.: Striatal neural grafting improves cortical metabolism in Huntingtons disease patients. Brain 127(Pt 1), 65-72 (2004).
84. Piccini P: Neurodegenerative movement disorders: the contribution of functional imaging. Curr. Opin. Neurol. 17(4), 459-466 (2004).
85. Freeman TB, Cicchetti F, Hauser RA et al.: Transplanted fetal striatum in Huntingtons disease: phenotypic development and lack of pathology. Proc. Natl Acad. Sci. USA 97(25), 13877-13882 (2000).
86. Kordower JH, Chu YP, Hauser RA, Freeman TB, Olanow CW: Lewy body-like pathology in long-term embryonic nigral transplants in Parkinsons disease. Nat. Med. 14(5), 504-506 (2008).
87. Li JY, Englund E, Holton JL et al.: Lewy bodies in grafted neurons in subjects with Parkinsons disease suggest host-to-graft disease propagation. Nat. Med. 14(5), 501-503 (2008).
88. Mendez I, Vinuela A, Astradsson A et al.: Dopamine neurons implanted into people with Parkinsons disease survive without pathology for 14 years. Nat. Med. 14(5), 507-509 (2008).
89. Cooper O, Astradsson A, Hallett P, Robertson H, Mendez I, Isacson O: Lack of functional relevance of isolated cell damage in transplants of Parkinsons disease patients. J. Neurol. 256(Suppl. 3), 310-316 (2009).
90. Cicchetti F, Saporta S, Hauser RA et al.: Neural transplants in patients with Huntingtons disease undergo disease-like neuronal degeneration. Proc. Natl Acad. Sci. USA 106(30), 12483-12488 (2009).
91. Krystkowiak P, Gaura V, Labalette M et al.: Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntingtons disease. PLoS One 2(1), E166 (2007).
92. Kelly CM, Precious SV, Torres EM et al.: Medical abortion: a more reliable source of tissue for cell replacement therapy. Cell Transplant. DOI: 10.3727/096368910X546580 (2010) (Epub ahead of print).
93. Albin RL: Fetal striatal transplantation in Huntingtons disease: time for a pause. J. Neurol. Neurosurg. Psychiat. 73(6), 611-612 (2002).
94. Gutekunst CA, Norflus F, Hersch SM: The neuropathology of Huntingtons disease. In: Huntingtons Disease. Bates G, Harper P, Jones L (Eds). Oxford University Press, UK, 251-275 (2002).
95. Sofroniew MV, Dunnett SB, Isacson O: Remodeling of intrinsic and afferent systems in neocortex with cortical transplants. Prog. Brain Res. 82, 313-320 (1990).
96. Mori F, Himes BT, Kowada M, Murray M, Tessler A: Fetal spinal cord transplants rescue some axotomized rubrospinal neurons from retrograde cell death in adult rats. Exp. Neurol. 143(1), 45-60 (1997).
97. Bernstein-Goral H, Bregman BS: Axotomized rubrospinal neurons rescued by fetal spinal cord transplants maintain axon collaterals to rostral CNS targets. Exp. Neurol. 148(1), 13-25 (1997).
98. Gonzalez MF, Sharp FR, Loken JE: Fetal frontal cortex transplanted to injured motor/sensory cortex of adult rats: reciprocal connections with host thalamus demonstrated with WGA-HRP. Exp. Neurol. 99(1), 154-165 (1988).
99. Dunnett SB: Functional repair of striatal systems by neural transplants: evidence for circuit reconstruction. Behav. Brain Res. 66, 133-142 (1995).
100. Svendsen CN, Clarke DJ, Rosser AE, Dunnett SB: Survival and differentiation of rat and human EGF responsive precursor cells following grafting into the lesioned adult CNS. Exp. Neurol. 137(2), 376-388 (1996).
101. Kelly CM, Zietlow R, Dunnett SB, Rosser AE: The effects of various concentrations of FGF-2 on the proliferation and neuronal yield of murine embryonic neural precursor cells in vitro. Cell Transplant. 12(3), 215-223 (2003).
102. Zietlow R, Pekarik V, Armstrong RJE, Tyers P, Dunnett SB, Rosser AE: The survival of neural precursor cell grafts is influenced by in vitro expansion. J. Anat. 207, 227-240 (2005).
103. Kelly CM, Tyers P, ter Borg M, Svendsen CN, Dunnett SB, Rosser AE: EGF and FGF-2 responsiveness of rat and mouse neural precursors derived from embryonic CNS. Brain Res. Bull. 68, 83-94 (2005).
104. Ostenfeld T, Joly E, Tai YT et al.: Regional specification of rodent and human neurospheres. Dev. Brain Res. 134(1-2), 43-55 (2002).
105. Kelly CM, Dunnett SB, Rosser AE: Medium spiny neurons for transplantation in Huntingtons disease. Biochem. Soc. Trans. 37(Pt 1), 323-328 (2009).
106. Armstrong RJE, Watts C, Svendsen CN, Dunnett SB, Rosser AE: Survival, neuronal integration and fibre outgrowth of propagated human neural precursor grafts in an animal model of Huntingtons disease. Cell Transplant. 9(1), 55-64 (2000).
107. Hurelbrink CB, Armstrong RJE, Dunnett SB, Rosser AE, Barker RA: Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. Eur. J. Neurosci. 15(7), 1255-1266 (2002).
108. Englund U, Björklund A, Wictorin K: Migration patterns and phenotypic differentiation of long-term expanded human neural progenitor cells after transplantation into the adult rat brain. Dev. Brain Res. 134(1-2), 123-141 (2002). (Pubitemid 34310243)
109. Fricker RA, Carpenter MK, Winkler C, Greco C, Gates MA, Björklund A: Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. J. Neurosci. 19(14), 5990-6005 (1999).
110. Ostenfeld T, Caldwell MA, Prowse KR, Linskens MH, Jauniaux E, Svendsen CN: Human neural precursor cells express low levels of telomerase in vitro and show diminishing cell proliferation with extensive axonal outgrowth following transplantation. Exp. Neurol. 164(1), 215-226 (2000).
111. Svendsen CN, Caldwell MA, Shen J et al.: Long term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinsons disease. Exp. Neurol. 148, 135-146 (1997).
112. Kim JB, Greber B, Arauzo-Bravo MJ et al.: Direct reprogramming of human neural stem cells by OCT4. Nature 461(7264), 649-643 (2009).
113. McBride JL, Behrstock SP, Chen EY et al.: Human neural stem cell transplants improve motor function in a rat model of Huntingtons disease. J. Comp. Neurol. 475(2), 211-219 (2004).
114. McLaren FH, Svendsen CN, Van der Meide P, Joly E: Analysis of neural stem cells by flow cytometry: cellular differentiation modifies patterns of MHC expression. J. Neuroimmunol. 112(1-2), 35-46 (2001).
115. Odeberg J, Piao JH, Samuelsson EB, Falci S, Akesson E: Low immunogenicity of in vitro-expanded human neural cells despite high MHC expression. J. Neuroimmunol. 161(1-2), 1-11 (2005).
116. Lee SH, Lumelsky N, Studer L, Auerbach JM, McKay RD: Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat. Biotechnol. 18(6), 675-679 (2000).
117. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA: Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12(11), 1259-1268 (2006).
118. Rolletschek A, Chang H, Guan K, Czyz J, Meyer M, Wobus AM: Differentiation of embryonic stem cell-derived dopaminergic neurons is enhanced by survival-promoting factors. Mech. Dev. 105(1-2), 93-104 (2001).
119. Okabe S, Forsberg-Nilsson K, Spiro AC, Segal M, McKay RD: Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro. Mech. Dev. 59(1), 89-102 (1996).
120. Kawasaki H, Mizuseki K, Nishikawa S et al.: Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 28(1), 31-40 (2000).
121. Kim JH, Auerbach JM, Rodriguez-Gomez JA et al.: Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinsons disease. Nature 418, 50-56 (2002).
122. Hedlund E, Pruszak J, Lardaro T et al.: Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinsons disease. Stem Cells 26(6), 1526-1536 (2008).
123. Friling S, Andersson E, Thompson LH et al.: Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc. Natl Acad. Sci. USA 106(18), 7613-7618 (2009).
124. Jonsson ME, Ono Y, Björklund A, Thompson LH: Identification of transplantable dopamine neuron precursors at different stages of midbrain neurogenesis. Exp. Neurol. 219(1), 341-354 (2009).
125. Thompson L, Barraud P, Andersson E, Kirik D, Björklund A: Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J. Neurosci. 25(27), 6467-6477 (2005).
126. Bouhon IA, Kato H, Chandran S, Allen ND: Neural differentiation of mouse embryonic stem cells in chemically defined medium. Brain Res. Bull. 68(1-2), 62-75 (2005).
127. Bouhon IA, Joannides A, Kato H, Chandran S, Allen ND: Embryonic stem cell derived neural progenitors display temporal restriction to neural patterning. Stem Cells 24(8), 1908-1913 (2006).
128. Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL: Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc. Natl Acad. Sci. USA 105(43), 16707-16712 (2008).
129. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L: Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27(3), 275-280 (2009).
130. Björklund L, Snchez-Pernaute R, Chung S et al.: Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl Acad. Sci. USA 99(4), 2344-2349 (2002).
131. Joannides AJ, Webber DJ, Raineteau O et al.: Environmental signals regulate lineage choice and temporal maturation of neural stem cells from human embryonic stem cells. Brain 130, 1263-1275 (2007).
132. Schuldiner M, Itskovitz-Eldor J, Benvenisty N: Selective ablation of human embryonic stem cells expressing a suicide gene. Stem Cells 21(3), 257-265 (2003).
133. Fareed MU, Moolten FL: Suicide gene transduction sensitizes murine embryonic and human mesenchymal stem cells to ablation on demand - a fail-safe protection against cellular misbehavior. Gene Ther. 9(14), 955-962 (2002).
134. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006).
135. Takahashi K, Tanabe K, Ohnuki M et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5), 861-872 (2007).
136. Yu J, Vodyanik MA, Smuga-Otto K et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858), 1917-1920 (2007).
137. Park IH, Zhao R, West JA et al.: Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451(7175), 141-146 (2008).
138. Cho HJ, Lee CS, Kwon YW et al.: Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Blood 116(3), 386-395 (2010).
139. Du L, Lin G, Lu G: Generation and identification of pluripotent stem cells from human embryonic fibroblast cells by four defined factors. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34(12), 1157-1165 (2009).
140. Giorgetti A, Montserrat N, Rodriguez-Piza I, Azqueta C, Veiga A, Izpisua Belmonte JC: Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2. Nat. Protoc. 5(4), 811-820 (2010).
141. Kim JB, Zaehres H, Arauzo-Bravo MJ, Scholer HR: Generation of induced pluripotent stem cells from neural stem cells. Nat. Protoc. 4(10), 1464-1470 (2009).
142. Li W, Zhou H, Abujarour R et al.: Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells 27(12), 2992-3000 (2009).
143. Okita K, Hong H, Takahashi K, Yamanaka S: Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat. Protoc. 5(3), 418-428 (2010).
144. Ross PJ, Suhr S, Rodriguez RM et al.: Human induced pluripotent stem cells produced under xeno-free conditions. Stem Cells Dev. 19(8), 1221-1229 (2009).
145. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M: Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463(7284), 1035-1041 (2010).
146. Zhao XY, Li W, Lv Z et al.: Efficient and rapid generation of induced pluripotent stem cells using an alternative culture medium. Cell Res. 20(3), 383-386 (2010).
147. Park IH, Arora N, Huo H et al.: Disease-specific induced pluripotent stem cells. Cell 134(5), 877-886 (2008).
148. Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA: Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 366(9502), 2019-2025 (2005).
149. Hu BY, Weick JP, Yu J et al.: Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl Acad. Sci. USA 107(9), 4335-4340 (2010).
150. Gallina P, Paganini M, Lombardini L et al.: Development of human striatal anlagen after transplantation in a patient with Huntingtons disease. Exp. Neurol. 213(1), 241-244 (2008).
151. Furtado S, Sossi V, Hauser RA et al.: Positron emission tomography after fetal transplantation in Huntingtons disease. Ann. Neurol. 58(2), 331-337 (2005).
152. Philpott LM, Kopyov OV, Lee AJ et al.: Neuropsychological functioning following fetal striatal transplantation in Huntingtons chorea: three case presentations. Cell Transplant. 6, 203-212 (1997).
153. Madrazo I, Franco-Bourland RE, Castrejon H, Cuevas C, Ostrosky-Solis F: Fetal striatal homotransplantation for Huntingtons disease: first two case reports. Neurol. Res. 17(4), 312-315 (1995).
154. Sramka M, Rattaj M, Molina H, Vojtassak J, Belan V, Ruzicky E: Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntingtons chorea. Stereotact. Funct. Neurosurg. 58, 79-83 (1992).
155. Keene CD, Sonnen JA, Swanson PD et al.: Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 68(24), 2093-2098 (2007).
156. Medical Research Council: Data and tissues tool kit www.dt-toolkit.ac.uk/ home.cfm
157. Department of Health: Abortion statistics, England & Wales, 2009 www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/ DH-116039